|
May 23
|
New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients
|
|
May 22
|
FDA Approves Genentech’s Susvimo for Diabetic Retinopathy
|
|
May 22
|
FDA approves Roche’s Susvimo for diabetic retinopathy
|
|
May 21
|
Roche strikes second Orionis deal to develop ‘molecular glues’ for cancer
|
|
May 21
|
Lilly’s former small molecule head makes the leap to a rising biotech in obesity
|
|
May 20
|
Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
|
|
May 20
|
Roche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
|
|
May 17
|
Trump administration not backing down on Big Pharma pressure campaign
|
|
May 16
|
Trump Trade: Trump asks Apple to stop building iPhone plants in India
|
|
Mar 10
|
Roche announces hub for cardiovascular, renal and metabolism research
|
|
Mar 7
|
Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston
|
|
Mar 5
|
FDA Accepts RHHBY's sNDA for Gazyva in Treating Lupus Nephritis
|
|
Mar 5
|
FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
|
|
Mar 5
|
FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis
|
|
Mar 4
|
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults
|
|
Mar 4
|
Why Recursion Pharmaceuticals, Inc. (RXRX) Crashed on Monday
|
|
Feb 20
|
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
|
|
Feb 19
|
Q4 2024 Halozyme Therapeutics Inc Earnings Call
|
|
Feb 14
|
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
|
|
Feb 12
|
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
|